Integrated

Transcend Therapeutics, Inc., established in 1992 in Waltham, Massachusetts, is a clinical-stage company focused on developing pharmaceuticals to address diseases associated with oxidative stress and tissue damage. The company aims to create psychoactive medicines targeting specific brain regions involved in neuropsychiatric disorders. By doing so, Transcend Therapeutics seeks to enable healthcare professionals to facilitate positive changes in brain function and behavior for patients suffering from these conditions.

BrainSpace collaborates with physicians, families, financial backers, and other parties with the purpose of eliminating the long-term handicap brought on by brain injury.

Homecoming is a provider of patient engagement tools tailored for psychedelic therapy. The company has developed a digital companion application that supports patients throughout their healing process. This application promotes accountability and long-term change by offering personalized guides, tasks, and daily check-ins, all within a user-friendly platform. It also facilitates preparation and integration support, enabling healthcare professionals to effectively guide their patients. Homecoming's focus on enhancing the therapeutic experience aims to improve outcomes for individuals undergoing psychedelic therapy.

Wellset Inc., founded in 2018 and located in Los Angeles, California, operates a comprehensive online platform designed to connect customers with wellness practitioners across various disciplines, including acupuncture, chiropractic care, massage therapy, nutrition, and health coaching. The platform not only facilitates the discovery and booking of these providers but also features a digital mental health studio that offers daily live classes and an extensive on-demand library. Users can access a wide range of holistic practices such as stretching, self-hypnosis, breathwork, and guided journaling. Wellset aims to support individuals in addressing their wellness needs by providing tailored access to qualified professionals and a variety of wellness resources.

Beckley Psytech Limited is a biotechnology company based in Oxford, United Kingdom, that develops psychedelic drugs aimed at treating psychiatric and neurological disorders. Founded in 2014, it focuses on harnessing the therapeutic potential of substances such as psilocybin to address significant mental health challenges, including depression and other debilitating neuropsychiatric conditions with considerable unmet needs. The company aims to integrate clinically validated psychedelic medicines into mainstream medical practices, offering patients innovative treatment options that differentiate from existing therapies. Through its drug pipeline, Beckley Psytech is committed to providing alternative solutions for those suffering from various mental health issues.

MycoMedica Life Sciences, founded by esteemed mycologist Paul Stamets, is a life sciences company dedicated to developing therapeutic drugs derived from fungi. The company focuses on harnessing the healing potential of the fungal genome to address psychiatric and neurological disorders. One of its key innovations, the Stamets Stack, combines unique ingredients that are not found together in nature to enhance the effectiveness of psilocybin for preventing and treating these conditions. MycoMedica aims to advance fungi-based drug development, offering new avenues for medical professionals to improve health outcomes and promote well-being.

Small Pharma Ltd. is a pharmaceutical company founded in 2015 and headquartered in London, United Kingdom. The company specializes in developing a rapid-acting antidepressant aimed at treating patients with depression. Small Pharma employs a scalable model of outsourced drug development, utilizing expert teams to design and execute development programs. This approach leverages academic discoveries and focuses on effective intellectual property design, ensuring that the various disciplines essential for successful drug development are addressed by qualified professionals.

Beckley Psytech Limited is a biotechnology company based in Oxford, United Kingdom, that develops psychedelic drugs aimed at treating psychiatric and neurological disorders. Founded in 2014, it focuses on harnessing the therapeutic potential of substances such as psilocybin to address significant mental health challenges, including depression and other debilitating neuropsychiatric conditions with considerable unmet needs. The company aims to integrate clinically validated psychedelic medicines into mainstream medical practices, offering patients innovative treatment options that differentiate from existing therapies. Through its drug pipeline, Beckley Psytech is committed to providing alternative solutions for those suffering from various mental health issues.